文献速递炎症性肠病

英夫利西单抗家庭输注与炎症性肠病不良结局相关且无成本节省

Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

基于Optum数据库2003至2016年27,396例炎症性肠病(IBD)患者(含1,839例儿童)的纵向数据分析显示,5.7%患者使用家庭英夫利西单抗输注;家庭输注者不依从率和停药率均高于门诊及医院输注,且未降低年度总体医疗费用。

要点

  • 家庭英夫利西单抗输注者不依从率22.2%,高于门诊19.8%和医院21.2%。
  • 家庭输注者停药率44.7%,高于门诊33.7%和医院33.4%。
  • 家庭输注未降低年度总体医疗费用,家庭组49,149美元 vs 门诊组43,466美元。

核心结论

  • IBD患者家庭英夫利西单抗输注与不依从率和停药率升高相关,且与门诊输注相比未带来显著成本节省。

研究设计与样本

  • 纵向患者数据来自Optum Clinformatics Data Mart,纳入2003至2016年所有接受英夫利西单抗治疗的IBD患者,共27,396例(含1,839例儿童)。

主要发现

  • 5.7%患者使用家庭英夫利西单抗输注。
  • 家庭输注者不依从率22.2%,高于门诊输注19.8%(P = .044)和医院输注21.2%(P < .001)。
  • 家庭输注者停药率44.7%,高于门诊输注33.7%(P < .001)和医院输注33.4%(P < .001)。
  • Kaplan-Meier分析显示,治疗第200天仍继续使用英夫利西单抗的概率分别为家庭输注64.4%、医院输注74.2%、门诊输注79.3%(P < .001)。
  • 家庭输注者累积激素使用天数最高(家庭238.2天、门诊189.7天、医院208.5天,P < .001),随访次数最少;家庭输注年度总体医疗费用49,149美元 vs 门诊输注43,466美元(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biologic agents including infliximab are effective but costly therapies in the management of inflammatory bowel disease (IBD). Home infliximab infusions are increasingly payer-mandated to minimize infusion-related costs. This study aimed to compare biologic medication use, health outcomes, and overall cost of care for adult and pediatric patients with IBD receiving home vs office- vs hospital-based infliximab infusions. METHODS: Longitudinal patient data were obtained from the Optum Clinformatics Data Mart. The analysis considered all patients with IBD who received infliximab from 2003 to 2016. Primary outcomes included nonadherence (≥2 infliximab infusions over 10 weeks apart in 1 year) and discontinuation of infliximab. Secondary outcomes included outpatient corticosteroid use, follow-up visits, emergency room visits, hospitalizations, surgeries, and cost outcomes (out-of-pocket costs and annual overall cost of care). RESULTS: There were 27,396 patients with IBD (1,839 pediatric patients). Overall, 5.7% of patients used home infliximab infusions. These patients were more likely to be nonadherent compared with both office-based (22.2% vs 19.8%; P = .044) and hospital-based infusions (22.2% vs 21.2%; P < .001). They were also more likely to discontinue infliximab compared with office-based (44.7% vs 33.7%; P < .001) or hospital-based (44.7% vs 33.4%; P < .001) infusions. On Kaplan-Meier analysis, the probabilities of remaining on infliximab by day 200 of therapy were 64.4%, 74.2%, and 79.3% for home-, hospital-, and office-based infusions, respectively (P < .001). Home infliximab patients had the highest corticosteroid use (cumulative corticosteroid days after IBD diagnosis: home based, 238.2; office based, 189.7; and hospital based, 208.5; P < .001) and the fewest follow-up visits. Home infusions did not decrease overall annual care costs compared with office infusions ($49,149 vs $43,466, P < .001). DISCUSSION: In this analysis, home infliximab infusions for patients with IBD were associated with suboptimal outcomes including higher rates of nonadherence and discontinuation of infliximab. Home infusions did not result in significant cost savings compared with office infusions.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Giese-Kim N, Wu M, Dehghan M, et al. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Am J Gastroenterol. 2020. PMID: 32701731. doi:10.14309/ajg.0000000000000750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。